MAP2K7 and Miyoshi myopathy: The analysis was extended to BRAFV600+ MM patients treated with dabrafenib plus trametinib, vemurafenib plus cobimetinib, or vemurafenib/dabrafenib alone, which act on the constitutively activated RAF–RAS–MEK–ERK pathway [47].